14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
CNCG vs HHS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNCG carries a Unified Composite Score of 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin), whereas HHS carries 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CNCG vs HHS. Trailing 12-month operating profitability (CNCG N/A vs HHS -3.2%) and valuation multiples (CNCG N/M vs HHS 14.3x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Conglomerates value chain with $30.0M market capitalization and -3.2% operating margin.
OpEx & R&D Reinvestment19.3% of Rev ($30M)
90D Engineering Disclosures0 Published
Investor FAQ CNCG vs HHS Key Questions & Quantitative Answers
As of Nov 16, 2026, Harte Hanks, Inc. (HHS) is the stronger overall head-to-head candidate over CNCG (CNCG) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CNCG carries a Unified Composite Score of 56.7/100 (HOLD) at $32.28 (N/M Forward P/E, N/A operating margin), whereas HHS carries 61.8/100 (BUY) at $3.84 (14.3x Forward P/E, -3.2% operating margin). Technically, CNCG sits in a Neutral phase (RSI 46.8, UNCLASSIFIED options structure) and HHS sits in a Neutral phase (RSI 38.2, UNCLASSIFIED options structure).
HHS leads the Growth & Scale pillar: CNCG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with HHS at -1.7% YoY revenue growth and -90.3% YoY earnings growth on $155M TTM revenue (16.1% gross margin, -3.2% operating margin). On trailing 12-month operating scale, CNCG generates N/A in USD-normalized revenue versus $155M for HHS. In operating R&D and SG&A reinvestment, CNCG deploys N/A (0 90-day corporate R&D disclosures) versus 19.3% of Rev ($30M) (0 disclosures) for HHS.
HHS screens cheaper on headline valuation multiples. CNCG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas HHS trades at 14.3x Forward P/E, 14.3x Trailing P/E, 1.19x PEG, and 0.3x EV/Revenue (-2.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CNCG (N/A ROE) versus HHS (-30.4% ROE) capital efficiency.
In options market volatility and institutional positioning, CNCG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.32β · 78% Vol realized risk). By comparison, HHS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.49β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.